Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
暂无分享,去创建一个
Arthur S Slutsky | M. Landray | P. Horby | J. Sterne | D. Annane | J. Marshall | D. Angus | S. Murthy | W. Lim | B. Giraudeau | J. Higgins | P. Jüni | J. Emberson | A. Gordon | F. Machado | L. Azevedo | F. Meziani | J. Villar | Janet Diaz | A. Perner | N. Heming | A. Cavalcanti | B. Du | J. Savović | R. Haynes | M. Møller | O. Berwanger | A. Granholm | M. W. Petersen | S. Webb | C. McArthur | V. Veiga | D. Fisher | A. Le Gouge | P. Dequin | B. Tomazini | Cameron Green | M. Leclerc | P. Jüni | J. Marshall
[1] Á. Avezum,et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. , 2020, JAMA.
[2] D. Annane,et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[3] Christopher M. Horvat,et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. , 2020, JAMA.
[4] Arthur S Slutsky,et al. Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials , 2020, Trials.
[5] Q. Bassat,et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] S. Abate,et al. Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: A systematic review and Meta-analysis , 2020, PloS one.
[7] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[8] P. Horby,et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.
[9] Herman Goossens,et al. The Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP CAP) study: rationale and design , 2020 .
[10] S. Pastores,et al. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019 , 2020, Critical care explorations.
[11] J. Baillie,et al. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.
[12] D. Annane,et al. Corticosteroids for treating sepsis in children and adults. , 2019, The Cochrane database of systematic reviews.
[13] W. Lim,et al. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. , 2019, Critical care medicine.
[14] J. Berlin,et al. Prospective approaches to accumulating evidence , 2019, Cochrane Handbook for Systematic Reviews of Interventions.
[15] Natalie S Blencowe,et al. RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.
[16] J. Berlin,et al. Chapter 22 : Prospective approaches to accumulating evidence , 2019 .
[17] D. Annane,et al. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. , 2018, Critical care medicine.
[18] G. Van den Berghe,et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017 , 2018, Intensive Care Medicine.
[19] J. Carpenter,et al. Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? , 2017, British Medical Journal.
[20] Dean Langan,et al. Comparative performance of heterogeneity variance estimators in meta‐analysis: a review of simulation studies , 2016, Research synthesis methods.
[21] W. Lim,et al. Corticosteroids as adjunctive therapy in the treatment of influenza. , 2016, The Cochrane database of systematic reviews.
[22] George F Borm,et al. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method , 2014, BMC Medical Research Methodology.
[23] Arthur S Slutsky,et al. Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .
[24] Djillali Annane,et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. , 2009, JAMA.
[25] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[26] J. Hartung,et al. A refined method for the meta‐analysis of controlled clinical trials with binary outcome , 2001, Statistics in medicine.
[27] John Mandel,et al. Consensus Values and Weighting Factors. , 1982, Journal of research of the National Bureau of Standards.
[28] R. Petersdorf,et al. Corticosteroids and infectious diseases. , 1973, The Medical clinics of North America.